|
시장보고서
상품코드
1587560
경비 약물 및 백신 전달 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용량별, 용도별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)Intranasal Drug And Vaccine Delivery Market Size, Share & Trends Analysis Report By Product, By Dosage (Deep Learning, Machine Learning), By Application, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
경비 약물 및 백신 전달 시장 성장과 동향
Grand View Research, Inc.의 최신 보고서에 따르면, 세계 경비 약물 및 백신 전달 시장 규모는 2030년까지 1,033억 3,300만 달러에 달할 것으로 추정되며, 2025-2030년까지 CAGR 6.6%로 성장할 것으로 예상됩니다.
비경구제나 경구제보다 비경구제나 경구제보다 비강용 제제를 선호하게 된 것이 시장을 주도하는 주요 요인 중 하나입니다.
수요 증가와 기술 발전은 주요 시장 촉진요인 중 하나입니다. 2020년 3월, Auris Medical Holding Ltd.는 급성 말초성 어지럼증 치료를 위한 경구용 베타히스틴(AM-125)의 임상 2상 시험에 대한 최신 정보를 제공했습니다. 제공하였습니다.
만성 호흡기질환의 유병률 증가는 비강 약물 및 백신 장치에 대한 수요를 증가시킬 것입니다. 미국 질병예방통제센터(CDC)에 따르면 2019년 13명 중 1명이 천식을 앓고 있으며, 2,500만 명 이상의 미국인이 천식을 앓고 있으며, 천식은 연간 약 1,420만 건의 병원 진료, 439,000건의 병원 퇴원, 1,800만 건의 응급실 방문을 차지한다고 CDC는 밝혔습니다. 차지하고 있다고 밝혔습니다.
액체 전달 장치는 수용액, 에멀전, 현탁액 등 다양한 제형으로 제공되기 때문에 2019년 시장을 장악했습니다. 단위 제제 부문은 다양한 질병 치료에 대한 승인 증가로 인해 유리한 성장을 보일 것으로 예상됩니다. 또한, 개발 중인 대부분의 백신 제제는 1회용 제제이며, 의료진은 일반적으로 1회용 비강 백신 접종을 권장하고 있습니다.
아시아태평양은 예측 기간 동안 가장 빠르게 성장하는 지역 시장이 될 것으로 예상됩니다. 이는 주로 제품 개발 프로토콜의 증가, 경제 성장, 새로운 약물전달 시스템 개발에 참여하는 현지 시장 진출 기업의 증가에 기인합니다.
경비 약물 및 백신 전달 시장 보고서 하이라이트
- 액체 전달 장치가 2024년 43.7%의 매출 점유율로 시장을 장악했습니다. 정량적 분무 펌프를 포함한 이러한 장치는 첫 번째 통과 대사를 피하고 생체 이용률을 높이며 치료 효과를 촉진합니다.
- 다회투여 시스템은 2024년 64.1%의 매출 점유율로 시장을 선도할 것으로 예상됩니다. 다중 투여 시스템은 내약성과 편의성을 향상시켜 환자가 적은 보충량으로 약물을 자가 투여할 수 있도록 돕습니다.
- 호흡기질환은 천식, COPD, 알레르기성 비염 등의 증상에 대한 비강 투여의 효과로 인해 2024년 41.1%의 가장 큰 시장 점유율을 차지했습니다.
- 소매약국은 2024년 45.1%의 점유율을 차지하며 시장을 장악했습니다. 이는 환자들의 인식이 높아지고 약물을 스스로 투여하는 경향이 높아진 데 따른 것입니다.
목차
제1장 조사 방법과 범위
제2장 주요 요약
제3장 경비 약물 및 백신 전달 시장 변수, 동향, 범위
- 시장 계통 전망
- 시장 역학
- 시장 성장 촉진요인 분석
- 시장 성장 억제요인 분석
- 비즈니스 환경 분석
- 산업 분석 - Porter's Five Forces 분석
- PESTLE 분석
제4장 경비 약물 및 백신 전달 시장 : 제품 비즈니스 분석
- 제품 시장 점유율, 2024년과 2030년
- 제품 부문 대시보드
- 시장 규모와 예측과 동향 분석, 제품별, 2018-2030년
- 분말 전달 디바이스
- 액체 전달 디바이스(정량 분무 펌프)
- 가압식 정량 흡입기
- 기타
제5장 경비 약물 및 백신 전달 시장 : 용량 비즈니스 분석
- 용량 시장 점유율, 2024년과 2030년
- 용량 부문 대시보드
- 시장 규모와 예측과 동향 분석, 용량별, 2018-2030년
- 일회 투여
- 다회 투여
제6장 경비 약물 및 백신 전달 시장 : 용도 비즈니스 분석
- 용도 시장 점유율, 2024년과 2030년
- 용도 부문 대시보드
- 시장 규모와 예측과 동향 분석, 용도별, 2018-2030년
- 호흡기질환
- 신경질환
- 예방 접종
- 통증 관리
- 기타
제7장 경비 약물 및 백신 전달 시장 : 유통 채널 비즈니스 분석
- 유통 채널 시장 점유율, 2024년과 2030년
- 유통 채널 부문 대시보드
- 시장 규모와 예측과 동향 분석, 유통 채널별, 2018-2030년
- 병원 약국
- 소매 약국
- 온라인 약국
제8장 경비 약물 및 백신 전달 시장 : 제품, 용량, 용도, 유통 채널별 지역별, 추정·동향 분석
- 지역별 시장 점유율 분석, 2024년과 2030년
- 지역별 시장 대시보드
- 시장 규모, 예측 동향 분석, 2018-2030년
- 북미
- 국가별, 2018-2030년
- 미국
- 캐나다
- 멕시코
- 유럽
- 국가별, 2018-2030년
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 노르웨이
- 덴마크
- 스웨덴
- 아시아태평양
- 국가별, 2018-2030년
- 일본
- 중국
- 인도
- 한국
- 호주
- 태국
- 라틴아메리카
- 국가별, 2018-2030년
- 브라질
- 아르헨티나
- 중동 및 아프리카
- 국가별, 2018-2030년
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트
제9장 경쟁 상황
- 참여자 개요
- 기업의 시장 포지션 분석
- 기업 분류
- 전략 매핑
- 기업 개요/상장 기업
- GSK plc
- Teva Pharmaceutical Industries Ltd
- AptarGroup, Inc.
- UCB SA, Belgium
- Teleflex Incorporated
- 3M
- Bespak Limited
- Optinose
- Intersect ENT
Intranasal Drug And Vaccine Delivery Market Growth & Trends:
The global intranasal drug and vaccine delivery market size is estimated to reach USD 103.33 billion by 2030, registering to grow at a CAGR of 6.6% from 2025 to 2030 according to a new report by Grand View Research, Inc. Increasing preference for nasal products over parenteral and oral formulations for instant relief is one of the major factors driving the market.
Increasing demand and advancements in technology are some of the major market drivers. Rising investment in research and development has escalated the clinical trial programs indicated for the treatment of various conditions. In March 2020, Auris Medical Holding Ltd. provided the Phase 2 trial update for intranasal betahistine (AM-125) for the treatment of acute peripheral vertigo.
Increasing prevalence of chronic respiratory disorders augments the demand for intranasal drug and vaccine devices as they are commonly prescribed by medical professionals owing to the easy self-administration technique. According to the Centers for Disease Control and Prevention (CDC), in 2019, 1 in 13 people have asthma, with more than 25 million Americans living with asthma. CDC also stated that asthma accounted for an estimated 14.2 million hospital visits, 439,000 hospital discharges, and 1.8 million emergency department visits annually.
Liquid delivery devices dominated the market in 2019 on account of their availability in various formulations, including aqueous solutions, emulsions, and suspensions. The unit-does segment is anticipated to witness lucrative growth due to increasing approvals for the treatment of various disorders. Moreover, majority of the vaccine formulations under development are unit-dose formulations as single intranasal vaccine dose is commonly recommended by medical professionals.
Asia Pacific is expected to emerge as the fastest growing regional market over the forecast period. This is primarily attributed to increasing product development protocols, economic growth, and increase in the number of local market players involved in the development of novel drug delivery systems.
Intranasal Drug And Vaccine Delivery Market Report Highlights:
- Liquid delivery devices dominated the market with a revenue share of 43.7% in 2024. These devices, including metered spray pumps, circumvent first-pass metabolism, enhancing bioavailability and accelerating therapeutic effects.
- Multi-dose systems led the market with a revenue share of 64.1% in 2024. Multi-dose systems provide improved tolerance and convenience, enabling patients to self-administer medications with fewer refills.
- Respiratory disorders held the largest market share of 41.1% in 2024, owing to the efficacy of intranasal delivery for conditions such as asthma, COPD, and allergic rhinitis.
- Retail pharmacies dominated the market and accounted for a share of 45.1% in 2024, fueled by rising patient awareness and a growing trend towards self-administration of medications.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Dosage
- 1.2.3. Application
- 1.2.4. Distribution Channel
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Intranasal Drug and Vaccine Delivery Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
Chapter 4. Intranasal Drug and Vaccine Delivery Market: Product Business Analysis
- 4.1. Product Market Share, 2024 & 2030
- 4.2. Product Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
- 4.4. Powder Delivery Device
- 4.4.1. Powder Delivery Device Market, 2018 - 2030 (USD Million)
- 4.5. Liquid Delivery Device (Metered Spray Pumps)
- 4.5.1. Liquid Delivery Device (Metered Spray Pumps) Market, 2018 - 2030 (USD Million)
- 4.6. Pressurized Metered Dose Inhaler
- 4.6.1. Pressurized Metered Dose Inhaler Market, 2018 - 2030 (USD Million)
- 4.7. Others
- 4.7.1. Others Market, 2018 - 2030 (USD Million)
Chapter 5. Intranasal Drug and Vaccine Delivery Market: Dosage Business Analysis
- 5.1. Dosage Market Share, 2024 & 2030
- 5.2. Dosage Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Dosage, 2018 to 2030 (USD Million)
- 5.4. Unit-dose
- 5.4.1. Unit-dose Market, 2018 - 2030 (USD Million)
- 5.5. Multi-dose
- 5.5.1. Multi-dose Market, 2018 - 2030 (USD Million)
Chapter 6. Intranasal Drug and Vaccine Delivery Market: Application Business Analysis
- 6.1. Application Market Share, 2024 & 2030
- 6.2. Application Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
- 6.4. Respiratory Disorders
- 6.4.1. Respiratory Disorders Market, 2018 - 2030 (USD Million)
- 6.5. Neurological Disorders
- 6.5.1. Neurological Disorders Market, 2018 - 2030 (USD Million)
- 6.6. Vaccination
- 6.6.1. Vaccination Market, 2018 - 2030 (USD Million)
- 6.7. Pain Management
- 6.7.1. Pain Management Market, 2018 - 2030 (USD Million)
- 6.8. Others
- 6.8.1. Others Market, 2018 - 2030 (USD Million)
Chapter 7. Intranasal Drug and Vaccine Delivery Market: Distribution Channel Business Analysis
- 7.1. Distribution Channel Market Share, 2024 & 2030
- 7.2. Distribution Channel Segment Dashboard
- 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
- 7.4. Hospital Pharmacies
- 7.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
- 7.5. Retail Pharmacies
- 7.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
- 7.6. Online Pharmacies
- 7.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)
Chapter 8. Intranasal Drug and Vaccine Delivery Market: Regional Estimates & Trend Analysis by Product, Dosage, Application, and Distribution Channel
- 8.1. Regional Market Share Analysis, 2024 & 2030
- 8.2. Regional Market Dashboard
- 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 8.4. North America
- 8.4.1. North America Intranasal Drug and Vaccine Delivery Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 8.4.2. U.S.
- 8.4.2.1. Key Country Dynamics
- 8.4.2.2. Regulatory Framework
- 8.4.2.3. Competitive Insights
- 8.4.2.4. U.S. Intranasal Drug and Vaccine Delivery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.4.3. Canada
- 8.4.3.1. Key Country Dynamics
- 8.4.3.2. Regulatory Framework
- 8.4.3.3. Competitive Insights
- 8.4.3.4. Canada Intranasal Drug and Vaccine Delivery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.4.4. Mexico
- 8.4.4.1. Key Country Dynamics
- 8.4.4.2. Regulatory Framework
- 8.4.4.3. Competitive Insights
- 8.4.4.4. Mexico Intranasal Drug and Vaccine Delivery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.5. Europe
- 8.5.1. Europe Intranasal Drug and Vaccine Delivery Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 8.5.2. UK
- 8.5.2.1. Key Country Dynamics
- 8.5.2.2. Regulatory Framework
- 8.5.2.3. Competitive Insights
- 8.5.2.4. UK Intranasal Drug and Vaccine Delivery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.5.3. Germany
- 8.5.3.1. Key Country Dynamics
- 8.5.3.2. Regulatory Framework
- 8.5.3.3. Competitive Insights
- 8.5.3.4. Germany Intranasal Drug and Vaccine Delivery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.5.4. France
- 8.5.4.1. Key Country Dynamics
- 8.5.4.2. Regulatory Framework
- 8.5.4.3. Competitive Insights
- 8.5.4.4. France Intranasal Drug and Vaccine Delivery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.5.5. Italy
- 8.5.5.1. Key Country Dynamics
- 8.5.5.2. Regulatory Framework
- 8.5.5.3. Competitive Insights
- 8.5.5.4. Italy Intranasal Drug and Vaccine Delivery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.5.6. Spain
- 8.5.6.1. Key Country Dynamics
- 8.5.6.2. Regulatory Framework
- 8.5.6.3. Competitive Insights
- 8.5.6.4. Spain Intranasal Drug and Vaccine Delivery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.5.7. Norway
- 8.5.7.1. Key Country Dynamics
- 8.5.7.2. Regulatory Framework
- 8.5.7.3. Competitive Insights
- 8.5.7.4. Norway Intranasal Drug and Vaccine Delivery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.5.8. Denmark
- 8.5.8.1. Key Country Dynamics
- 8.5.8.2. Regulatory Framework
- 8.5.8.3. Competitive Insights
- 8.5.8.4. Denmark Intranasal Drug and Vaccine Delivery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.5.9. Sweden
- 8.5.9.1. Key Country Dynamics
- 8.5.9.2. Regulatory Framework
- 8.5.9.3. Competitive Insights
- 8.5.9.4. Sweden Intranasal Drug and Vaccine Delivery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.6. Asia Pacific
- 8.6.1. Asia Pacific Intranasal Drug and Vaccine Delivery Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 8.6.2. Japan
- 8.6.2.1. Key Country Dynamics
- 8.6.2.2. Regulatory Framework
- 8.6.2.3. Competitive Insights
- 8.6.2.4. Japan Intranasal Drug and Vaccine Delivery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.6.3. China
- 8.6.3.1. Key Country Dynamics
- 8.6.3.2. Regulatory Framework
- 8.6.3.3. Competitive Insights
- 8.6.3.4. China Intranasal Drug and Vaccine Delivery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.6.4. India
- 8.6.4.1. Key Country Dynamics
- 8.6.4.2. Regulatory Framework
- 8.6.4.3. Competitive Insights
- 8.6.4.4. India Intranasal Drug and Vaccine Delivery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.6.5. South Korea
- 8.6.5.1. Key Country Dynamics
- 8.6.5.2. Regulatory Framework
- 8.6.5.3. Competitive Insights
- 8.6.5.4. South Korea Intranasal Drug and Vaccine Delivery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.6.6. Australia
- 8.6.6.1. Key Country Dynamics
- 8.6.6.2. Regulatory Framework
- 8.6.6.3. Competitive Insights
- 8.6.6.4. Australia Intranasal Drug and Vaccine Delivery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.6.7. Thailand
- 8.6.7.1. Key Country Dynamics
- 8.6.7.2. Regulatory Framework
- 8.6.7.3. Competitive Insights
- 8.6.7.4. Thailand Intranasal Drug and Vaccine Delivery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.7. Latin America
- 8.7.1. Latin America Intranasal Drug and Vaccine Delivery Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 8.7.2. Brazil
- 8.7.2.1. Key Country Dynamics
- 8.7.2.2. Regulatory Framework
- 8.7.2.3. Competitive Insights
- 8.7.2.4. Brazil Intranasal Drug and Vaccine Delivery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.7.3. Argentina
- 8.7.3.1. Key Country Dynamics
- 8.7.3.2. Regulatory Framework
- 8.7.3.3. Competitive Insights
- 8.7.3.4. Argentina Intranasal Drug and Vaccine Delivery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.8. MEA
- 8.8.1. MEA Intranasal Drug and Vaccine Delivery Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 8.8.2. South Africa
- 8.8.2.1. Key Country Dynamics
- 8.8.2.2. Regulatory Framework
- 8.8.2.3. Competitive Insights
- 8.8.2.4. South Africa Intranasal Drug and Vaccine Delivery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.8.3. Saudi Arabia
- 8.8.3.1. Key Country Dynamics
- 8.8.3.2. Regulatory Framework
- 8.8.3.3. Competitive Insights
- 8.8.3.4. Saudi Arabia Intranasal Drug and Vaccine Delivery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.8.4. UAE
- 8.8.4.1. Key Country Dynamics
- 8.8.4.2. Regulatory Framework
- 8.8.4.3. Competitive Insights
- 8.8.4.4. UAE Intranasal Drug and Vaccine Delivery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.8.5. Kuwait
- 8.8.5.1. Key Country Dynamics
- 8.8.5.2. Regulatory Framework
- 8.8.5.3. Competitive Insights
- 8.8.5.4. Kuwait Intranasal Drug and Vaccine Delivery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
- 9.1. Participant Overview
- 9.2. Company Market Position Analysis
- 9.3. Company Categorization
- 9.4. Strategy Mapping
- 9.5. Company Profiles/Listing
- 9.5.1. GSK plc
- 9.5.1.1. Overview
- 9.5.1.2. Financial Performance
- 9.5.1.3. Product Benchmarking
- 9.5.1.4. Strategic Initiatives
- 9.5.2. Teva Pharmaceutical Industries Ltd
- 9.5.2.1. Overview
- 9.5.2.2. Financial Performance
- 9.5.2.3. Product Benchmarking
- 9.5.2.4. Strategic Initiatives
- 9.5.3. AptarGroup, Inc.
- 9.5.3.1. Overview
- 9.5.3.2. Financial Performance
- 9.5.3.3. Product Benchmarking
- 9.5.3.4. Strategic Initiatives
- 9.5.4. UCB S.A., Belgium
- 9.5.4.1. Overview
- 9.5.4.2. Financial Performance
- 9.5.4.3. Product Benchmarking
- 9.5.4.4. Strategic Initiatives
- 9.5.5. Teleflex Incorporated
- 9.5.5.1. Overview
- 9.5.5.2. Financial Performance
- 9.5.5.3. Product Benchmarking
- 9.5.5.4. Strategic Initiatives
- 9.5.6. 3M
- 9.5.6.1. Overview
- 9.5.6.2. Financial Performance
- 9.5.6.3. Product Benchmarking
- 9.5.6.4. Strategic Initiatives
- 9.5.7. Bespak Limited
- 9.5.7.1. Overview
- 9.5.7.2. Financial Performance
- 9.5.7.3. Product Benchmarking
- 9.5.7.4. Strategic Initiatives
- 9.5.8. Optinose
- 9.5.8.1. Overview
- 9.5.8.2. Financial Performance
- 9.5.8.3. Product Benchmarking
- 9.5.8.4. Strategic Initiatives
- 9.5.9. Intersect ENT
- 9.5.9.1. Overview
- 9.5.9.2. Financial Performance
- 9.5.9.3. Product Benchmarking
- 9.5.9.4. Strategic Initiatives
- 9.5.1. GSK plc
